EXTON, Pa.--(BUSINESS WIRE)--Adolor Corporation (Nasdaq:ADLR) today reported financial results for the three months ended March 31, 2009. Net product sales of ENTEREG® (alvimopan) recognized for the three months ended March 31, 2009 were approximately $1.4 million on total net shipments of approximately $2.0 million. Under Adolor's current revenue recognition policy, revenue related to a customer shipment is deferred until subsequent re-orders by that customer. Since the Company's launch of ENTEREG in June 2008, approximately 300 hospitals have re-ordered the product.
